[1] |
JIN Yiyi, ZHOU Keting, YANG Chengcheng, XU Ping, ZHU Suyan.
Osthole attenuates diabetes-induced renal injury by regulating NF-κB and p38/MAPK pathway mediated inflammatory responses
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 622-631.
|
[2] |
XU Ke, GAO Junwei, LIU Peng, SHEN Zhengri, JIA Hui, WU Chenguang, TIAN Feng, WANG Lifan, LI Ping.
Tangshen formula improves cholesterol uptake and efflux of macrophages induced by high lipid via activating PGC-1α/LXR/ABCA1 pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 978-985.
|
[3] |
ZHAO Shaojing, ZENG Yan, LI Zhengdong, ZHANG Hua.
Protective effects of L-carnitine on diabetic nephropathy in rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 278-282.
|
[4] |
YAO Jia, QIAO Di, GUO Xin, CUI Changmeng.
Therapeutic effects of 1-Deoxynojirimycin in mulberry leaves on rats with diabetic nephropathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 517-523.
|
[5] |
JIANG Lili, MAO Limin, HU Sijia, PENG Yingzhi.
Effects of Shenshuaining granules on the expression of NF-kB and PPAR-gamma in kidney tissue of diabetic nephropathy rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 132-137.
|
[6] |
FU Yongjin, XIA Xueyi, ZHANG Xiaomu, LIU Yanbo, PAN Jingqiang, LV Junhua.
Effects of tetramethylpyrazine on the down-regulation of HMGB1 expression and reducing contents of RAGEs in diabetic nephropathy rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 846-851.
|
[7] |
YU Xiaoyi, ZHOU Zhiruo, XIE Yuan, SUN Runbin, FEI Fei, GAO Haoxue, HUANG Jingqiu, A Jiye, WANG Guangji.
Preliminary study on mechanism of tricarboxylic acid cycle disruption in diabetic nephropathy cell model
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 481-489.
|
[8] |
FAN Qiu-ling, ZHAO Xiao-ming, PU Shi, LI Sa-li, YANG Gang, JIANG Yi, WANG Li-ning.
Effects of candesartan early or late treatment on angiotensinⅡtype 1 and type 2 receptor expression in type 2 diabetic KK/Ta mice kidney
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(6): 627-633.
|
[9] |
LIU Lei, LI Liang-Zhi, HE Xian-Hong, TANG Yue-wu, SHI Ji-hong, LIU Chun-qiu, WU Ze-cheng, WANG Jun.
Cinical study of Keluoxin combined with enalapril in treatment of diabetic nephropathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 211-214.
|
[10] |
HAN Su-fang.
Meta-Analysis of ACEI combined with ARB on the effect of renal function with Diabetic Nephropathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(11): 1257-1262.
|
[11] |
FEI Mei-jiao.
Clinic effects of irbesartan combined with glutathione sodium on kidney in patients with diabetic nephropathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(11): 1272-1275.
|
[12] |
REN Chuan-yong, XU Liang.
Observation for effect of alprostadil on uric albumin excretion of the patients with diabetic nephropathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(7): 812-814.
|
[13] |
NI Lian-song, JIN Jie-na, ZHENG Jing-chen, SHEN Fei-xia.
Effects of blocking of p38 MAPK on the signal passway of NF-κB in glomerular mesangial cells incubated with high concentration of glucose
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 13-17.
|
[14] |
SHEN Shui-juan, HU Zuo-xiang, WANG Shi-ming, LI Qing-hua.
Clinical curative effect observation of ambrette capsule combined with tripterygium glycosides tablet on diabetic nephropathy of IV stage
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 85-88.
|
[15] |
WANG Ya-min.
Progression of sulodexide and clinical application
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(1): 109-115.
|